Clinical Trial Update: Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update investigating a beta-3 agonist and an anti-muscarinic agent for Sjogren's syndrome with overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder
• Sjogren Syndrome

Snippet

Sponsor: China Medical University Hospital | Conditions: Sjogren's Syndrome, Overactive Bladder Syndrome | Phase 4 | Status: UNKNOWN